Lead Product(s) : AAV1-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Novasep Signs €4.7m Biomanufacturing Deal with Biotech
Details : Through the agreement, Novasep will support Celladon’s plans to produce Mydicar, which is being evaluated in the mid-stage clinical trial for the treatment of heart failure.
Brand Name : Mydicar
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : AAV1-based Therapy
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Celladon
Deal Size : $5.4 million
Deal Type : Agreement
Lead Product(s) : Omadacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Paratek Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration, Novasep and Paratek will manufacture NUZYRA® (omadacycline), an FDA-approved tetracycline-class, once-daily oral and intravenous antibiotic for the treatment of adults with CABP and acute bacterial skin and skin str...
Brand Name : Nuzyra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 15, 2022
Lead Product(s) : Omadacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Paratek Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Monomethyl Auristatin E-Conjugated Antibody
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : McSAF
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Novasep has successfully optimized and scaled-up the process of Adcitmer® (monomethyl auristatin E-conjugated antibody), McSAF Inside® Oncology’s first-in-class proprietary ADC to treat neuroendocrine cancers.
Brand Name : Adcitmer
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 18, 2021
Lead Product(s) : Monomethyl Auristatin E-Conjugated Antibody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : McSAF
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Teriflunomide
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Breckenridge Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Teriflunomide – API and Licensing Agreements for Tablets Available
Details : The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Brand Name : Teriflunomide-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 06, 2021
Lead Product(s) : Teriflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Breckenridge Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Novasep Secures Manufacturing Deal with US Biotech for ADC Drug Candidate
Details : Through the agreement, Novosep will perform the process development of the XB002 ADC. which is being evaluated in the early-stage clinical trial studies for the treatment of non-small cell lung cancer and cervical cancer.
Brand Name : XB002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
July 07, 2021
Lead Product(s) : OTOF-GT,Aav Vectors
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Details : Novasep will be in charge of developing and manufacturing the two AAV vectors designed for the Sensorion OTOF-GT project and will supply Drug Product batches to support preclinical and clinical studies.
Brand Name : OTOF-GT
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : OTOF-GT,Aav Vectors
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : LYS-GM101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Collaboration
Details : With this collaboration, the two companies consolidate their long-lasting partnership initiated with the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, currently in clinical phase 2/3.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 26, 2020
Lead Product(s) : LYS-GM101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Lysogene
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
Sensorion and Novasep Sign Agreement
Details : The agreement aims for the manufacturing of adeno-associated virus (AAV) vectors, covering the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein and aims to restore the expression of Otoferlin.
Brand Name : OTOF-GT
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 11, 2020
Lead Product(s) : OTOF-GT
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Sensorion
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
